

Supplementary Table 4. ElastQ cutoffs for different fibrosis risk groups amongst patients without any ascites

		ROC	95% CI	Cutoff (kPa)	Sens. (%)	Spec. (%)
Grey zone	Rule out	0.81	0.78–0.84	<5	0.89	0.38
	Rule in			≥6.7	0.58	0.91
ACLD	Rule out	0.90	0.87–0.92	<6.2	0.90	0.64
	Rule in			≥9	0.76	0.91

ROC, area under the receiver operator characteristics curve; 95% CI, 95% confidence interval; Sens., sensitivity; Spec., specificity; ACLD, advanced chronic liver disease.

Supplementary Table 5. Population characteristics by fibrosis risk group based on ElastQ

	No fibrosis (n=133)	Grey zone (n=418)	ACLD (n=265)	P-value
Sex				
Female	68 (51.1)	183 (43.8)	125 (47.2)	0.304
Male	65 (48.9)	235 (56.2)	140 (52.8)	
Age (year), median (IQR)	55.0 (24.0)	54.0 (19.8)	60.0 (17.0)	<0.001
BMI (m/kg ²), median (IQR)	25.7 (6.1)	25.0 (5.3)	25.9 (7.1)	0.010
Etiology				
ALD	6 (4.5)	27 (6.5)	49 (18.5)	<0.001
Viral hepatitis	1 (0.8)	14 (3.3)	14 (5.3)	
NAFLD	36 (27.1)	61 (14.6)	35 (13.2)	
Cholestatic/AIH	8 (6.0)	28 (6.7)	24 (9.1)	
Other/Cryptogenic	82 (61.7)	288 (68.9)	143 (54.0)	
AST (U/L), median (IQR)	28 (24)	28 (20)	45 (35)	<0.001
ALT (U/L)	31 (27)	29 (28)	40 (36)	<0.001
GGT (U/L), median (IQR)	23.0 (32.5)	33.0 (51.0)	104 (143)	<0.001
FIB 4 (points), median (IQR)	1.25 (1.06)	1.46 (1.21)	3.37 (4.25)	<0.001
Platelet (g/L), median (IQR)	214 (88)	201 (78)	134 (93)	<0.001
Albumin (g/dL), median (IQR)	44.9 (5.7)	44.0 (5.1)	38.7 (8.5)	<0.001
INR, median (IQR)	1.0 (0.12)	1.0 (0.11)	1.2 (0.30)	<0.001
Bilirubin (mg/dL), median (IQR)	0.62 (0.53)	0.65 (0.53)	0.94 (1.20)	<0.001
TE probe				
M	96 (72.2)	359 (85.9)	209 (78.9)	<0.001
XL	37 (27.8)	59 (14.1)	56 (21.1)	
VCTE-LSM (kPa), median (IQR)	4.9 (1.8)	6.1 (3.0)	18.0 (18.4)	<0.001
VCTE-LSM IQR/Med. (%), median (IQR)	14.0 (9.1)	13.0 (8.5)	13.0 (12.0)	0.404
CAP (dB/m), median (IQR)	255 (119)	243 (80)	239 (79)	0.064
CAP IQR (dB/m), median (IQR)	35 (32)	34 (24)	36 (22)	0.924
ElastQ-LSM median (kPa), median (IQR)	4.6 (6.2)	6.1 (1.3)	12.2 (3.9)	<0.001
ElastQ-LSM IQR/Med. (%), median (IQR)	8.4 (11.6)	10.6 (10.2)	8.9 (9.8)	0.003
Center				
Center 1	53 (39.8)	172 (41.1)	58 (21.9)	<0.001
Center 2	58 (43.6)	103 (24.6)	76 (28.7)	
Center 3	22 (16.5)	143 (34.2)	131 (49.4)	

Values are presented as number (%) unless otherwise indicated.

ACLD, advanced chronic liver disease; IQR, interquartile range; BMI, body mass index; ALD, alcoholic liver disease; NAFLD, non-alcoholic fatty liver disease; AIH, autoimmune hepatitis; AST, aspartate aminotransferase; ALT, alanine transaminase; GGT, gamma-glutamyl transferase; FIB 4, Fibrosis-4 score; INR, international normalized ratio; VCTE, vibration-controlled transient elastography; LSM, liver stiffness measurement; Med., median; CAP, controlled attenuation parameter.